• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Fate Therapeutics, Inc.

    Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Announces Leadership Transition
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics to Present at Upcoming December Investor Conferences
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics to Present at Upcoming March Investor Conferences
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FATE
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.